Dosimetric assessment of patient dose calculation on a deep learning-based synthesized computed tomography image for adaptive radiotherapy.

PURPOSE: Dose computation using cone beam computed tomography (CBCT) images is inaccurate for the purpose of adaptive treatment planning. The main goal of this study is to assess the dosimetric accuracy of synthetic computed tomography (CT)-based calculation for adaptive planning in the upper abdominal region. We hypothesized that deep learning-based synthetically generated CT images will produce comparable results to a deformed CT (CTdef) in terms of dose calculation, while displaying a more accurate representation of the daily anatomy and therefore superior dosimetric accuracy. METHODS: We have implemented a cycle-consistent generative adversarial networks (CycleGANs) architecture to synthesize CT images from the daily acquired CBCT image with minimal error. CBCT and CT images from 17 liver stereotactic body radiation therapy (SBRT) patients were used to train, test, and validate the algorithm. RESULTS: The synthetically generated images showed increased signal-to-noise ratio, contrast resolution, and reduced root mean square error, mean absolute error, noise, and artifact severity. Superior edge matching, sharpness, and preservation of anatomical structures from the CBCT images were observed for the synthetic images when compared to the CTdef registration method. Three verification plans (CBCT, CTdef, and synthetic) were created from the original treatment plan and dose volume histogram (DVH) statistics were calculated. The synthetic-based calculation shows comparatively similar results to the CTdef-based calculation with a maximum mean deviation of 1.5%. CONCLUSIONS: Our findings show that CycleGANs can produce reliable synthetic images for the adaptive delivery framework. Dose calculations can be performed on synthetic images with minimal error. Additionally, enhanced image quality should translate into better daily alignment, increasing treatment delivery accuracy.

Fiducial detection and registration for 3D IMRT QA with organ-specific dose information.

PURPOSE: Two-dimensional (2D) IMRT QA has been widely performed in Radiation Oncology clinic. However, concerns regarding its sensitivity in detecting delivery errors and its clinical meaning have been raised in publications. In this study, a robust methodology of three-dimensional (3D) IMRT QA using fiducial registration and structure-mapping was proposed to acquire organ-specific dose information. METHODS: Computed tomography (CT) markers were placed on the PRESAGE dosimeter as fiducials before CT simulation. Subsequently, the images were transferred to the treatment planning system to create a verification plan for the examined treatment plan. Patient's CT images were registered to the CT images of the dosimeter for structure mapping according to the positions of the fiducials. After irradiation, the 3D dose distribution was read-out by an optical-CT (OCT) scanner with fiducials shown on the OCT dose images. An automatic localization algorithm was developed in MATLAB to register the markers in the OCT images to those in the CT images of the dosimeter. SlicerRT was used to show and analyze the results. Fiducial registration error was acquired by measuring the discrepancies in 20 fiducial registrations, and thus the fiducial localization error and target registration error (TRE) was estimated. RESULTS: Dosimetry comparison between the calculated and measured dose distribution in various forms were presented, including 2D isodose lines comparison, 3D isodose surfaces with patient's anatomical structures, 2D and 3D gamma index, dose volume histogram and 3D view of gamma failing points. From the analysis of 20 fiducial registrations, fiducial registration error was measured to be 0.62 mm and fiducial localization error was calculated to be 0.44 mm. Target registration uncertainty of the proposed methodology was estimated to be within 0.3 mm in the area of dose measurement. CONCLUSIONS: This study proposed a robust methodology of 3D measurement-based IMRT QA for organ-specific dose comparison and demonstrated its clinical feasibility.

Dosimetric characterization of a body-conforming radiochromic sheet.

PURPOSE: A novel radiochromic PRESAGE sheet (Heuris Inc.) with 3 mm thickness has been developed as a measurement tool for 2D dosimetry. Its inherent ability to conform to irregular surfaces makes this dosimeter advantageous for patient surface dosimetry. This study is a comprehensive investigation into the PRESAGE sheet's dosimetric characteristic, accuracy and its potential use as a dosimeter for clinical applications. METHODS: The characterization of the dosimeter included evaluation of the temporal stability of the dose linearity, reproducibility, measurement uncertainties, dose rate, energy, temperature and angular dependence, lateral response artifacts, percent depth dose curve, and 2D dose measurement. Dose distribution measurements were acquired for regular square fields on a flat and irregular surface and an irregular modulated field on the smooth surface. All measurements were performed using an Epson 11000XL high-resolution scanner. RESULTS: The examined dosimeters exhibit stable linear response, standard error of repeated measurements within 2%, negligible dose rate, energy, and angular dependence. The same linear dose response was measured while the dosimeter was in contact with a heated water surface. Gamma test and histogram analysis of the dose difference between PRESAGE and EBT3 film, PRESAGE and the treatment planning system (TPS) were used to evaluate the measured dose distributions. The PRESAGE sheet dose distributions showed good agreement with EBT3 film and TPS. A discrepancy smaller than the statistical error of the two dosimeters was reported. CONCLUSIONS: This study established a full dosimetric characterization of the PRESAGE sheets with the purpose of laying the foundation for future clinical uses. The results presented here for the comparison of this novel dosimeter with those currently in use reinforce the possibility of using this dosimeter as an alternative for irregular surface dose measurements.

Fetal radiation monitoring and dose minimization during intensity modulated radiation therapy for glioblastoma in pregnancy.

We examined the fetal dose from irradiation of glioblastoma during pregnancy using intensity modulated radiation therapy (IMRT), and describe fetal dose minimization using mobile shielding devices. A case report is described of a pregnant woman with glioblastoma who was treated during the third trimester of gestation with 60 Gy of radiation delivered via a 6 MV photon IMRT plan. Fetal dose without shielding was estimated using an anthropomorphic phantom with ion chamber and diode measurements. Clinical fetal dose with shielding was determined with optically stimulated luminescent dosimeters and ion chamber. Clinical target volume (CTV) and planning target volume (PTV) coverage was 100 and 98 % receiving 95 % of the prescription dose, respectively. Normal tissue tolerances were kept below quantitative analysis of normal tissue effects in the clinic (QUANTEC) recommendations. Without shielding, anthropomorphic phantom measurements showed a cumulative fetal dose of 0.024 Gy. In vivo measurements with shielding in place demonstrated a cumulative fetal dose of 0.016 Gy. The fetal dose estimated without shielding was 0.04 % and with shielding was 0.026 % of the target dose. In vivo estimation of dose equivalent received by the fetus was 24.21 mSv. Using modern techniques, brain irradiation can be delivered to pregnant patients in the third trimester with very low measured doses to the fetus, without compromising target coverage or normal tissue dose constraints. Fetal dose can further be reduced with the use of shielding devices, in keeping with the principle of as low as reasonably achievable.

Comprehensive stereotactic radiosurgery platform characterization: A novel end-to-end approach with anthropomorphic 3D dosimetry.

BACKGROUND: Stereotactic radiosurgery (SRS) is a widely employed strategy for intracranial metastases, utilizing linear accelerators and volumetric modulated arc therapy (VMAT). Ensuring precise linear accelerator performance is crucial, given the small planning target volume (PTV) margins. Rapid dose falloff is vital to minimize brain radiation necrosis. Despite advances in SRS planning, tools for end-to-end testing of SRS treatments are lacking, hindering confidence in the procedure. PURPOSE: This study introduces a novel end-to-end three-dimensional (3D) anthropomorphic dosimetry system for characterization of a radiosurgery platform, aiming to measure planning metrics, dose gradient index (DGI), brain volumes receiving at least 10 and 12 Gy (V10, V12), as well as assess delivery uncertainties in multitarget treatments. The study also compares metrics from benchmark plans to enhance understanding and confidence in SRS treatments. METHODS: The developed anthropomorphic 3D dosimetry system includes a modified Stereotactic End-to-End Verification (STEEV) phantom with a customized insert integrating 3D dosimeters and a fiber optic CT scanner. Labview and MATLAB programs handle optical scanning, image preprocessing, and dosimetric analysis. SlicerRT is used for 3D dose visualization and analysis. A film stack insert was used to validate the 3D dosimeter measurements at specific slices. Benchmark plans were developed and measured to investigate off-axis errors, dose spillage, small field dosimetry, and multi-target delivery. RESULTS: The accuracy of the developed 3D dosimetry system was rigorously assessed using radiochromic films. Two two-dimensional (2D) dose planes, extracted from the 3D dose distribution, were compared with film measurements, resulting in high passing rates of 99.9% and 99.6% in gamma tests. The mean relative dose difference between film and 3D dosimeter measurements was -1%, with a standard deviation of 2.2%, well within dosimeter uncertainties. In the first module, evaluating single-isocenter multitarget treatments, a 1.5 mm dose distribution shift was observed when targets were 7 cm off-axis. This shift was attributed to machine mechanical errors and image-guided system uncertainties, indicating potential limitations in conventional gamma tests. The second module investigated discrepancies in intermediate-to-low dose spillage, revealing higher measured doses in the connecting region between closely positioned targets. This discrepancy was linked to uncertainties in treatment planning system (TPS) modeling of out-of-field dose and multileaf collimator (MLC) characteristics, resulting in lower DGI values and higher V10 and V12 values compared to TPS calculations. In the third module, irradiating multiple targets showed consistent V10 and V12 values within 1 cm3 agreement with dose calculations. However, lower DGI values from measurements compared to calculations suggested intricacies in the treatment process. Conducting vital end-to-end testing demonstrated the anthropomorphic 3D dosimetry system's capacity to assess overall treatment uncertainty, offering a valuable tool for enhancing treatment accuracy in radiosurgery platforms. CONCLUSIONS: The study introduces a novel anthropomorphic 3D dosimetry system for end-to-end testing of a radiosurgery platform. The system effectively measures plan quality metrics, captures mechanical errors, and visualizes dose discrepancies in 3D space. The comprehensive evaluation capability enhances confidence in the commissioning and verification process, ensuring patient safety. The system is recommended for commissioning new radiosurgery platforms and remote auditing of existing programs.

Synthetic CT for gamma knife radiosurgery dose calculation: A feasibility study.

PURPOSE: To determine if MRI-based synthetic CTs (sCT), generated with no predefined pulse sequence, can be used for inhomogeneity correction in routine gamma knife radiosurgery (GKRS) treatment planning dose calculation. METHODS: Two sets of sCTs were generated from T1post and T2 images using cycleGAN. Twenty-eight patients (18 training, 10 validation) were retrospectively selected. The image quality of the generated sCTs was compared with the original CT (oCT) regarding the HU value preservation using histogram comparison, RMSE and MAE, and structural integrity. Dosimetric comparisons were also made among GKRS plans from 3 calculation approaches: TMR10 (oCT), and convolution (oCT and sCT), at four locations: original disease site, bone/tissue interface, air/tissue interface, and mid-brain. RESULTS: The study showed that sCTs and oCTs' HU were similar, with T2-sCT performing better. TMR10 significantly underdosed the target by a mean of 5.4% compared to the convolution algorithm. There was no significant difference in convolution algorithm shot time between the oCT and sCT generated with T2. The highest and lowest dosimetric differences between the two CTs were observed in the bone and air interface, respectively. Dosimetric differences of 3.3% were observed in sCT predicted from MRI with stereotactic frames, which was not included in the training sets. CONCLUSIONS: MRI-based sCT can be utilized for GKRS convolution dose calculation without the unnecessary radiation dose, and sCT without metal artifacts could be generated in framed cases. Larger datasets inclusive of all pulse sequences can improve the training set. Further investigation and validation studies are needed before clinical implementation.

Validation of a High-Throughput Dicentric Chromosome Assay Using Complex Radiation Exposures.

Validation of biodosimetry assays is routinely performed using primarily orthovoltage irradiators at a conventional dose rate of approximately 1 Gy/min. However, incidental/ accidental exposures caused by nuclear weapons can be more complex. The aim of this work was to simulate the DNA damage effects mimicking those caused by the detonation of a several kilotons improvised nuclear device (IND). For this, we modeled complex exposures to: 1. a mixed (photons + IND-neutrons) field and 2. different dose rates that may come from the blast, nuclear fallout, or ground deposition of radionuclides (ground shine). Additionally, we assessed whether myeloid cytokines affect the precision of radiation dose estimation by modulating the frequency of dicentric chromosomes. To mimic different exposure scenarios, several irradiation systems were used. In a mixed field study, human blood samples were exposed to a photon field enriched with neutrons (ranging from 10% to 37%) from a source that mimics Hiroshima's A-bomb's energy spectrum (0.2-9 MeV). Using statistical analysis, we assessed whether photons and neutrons act in an additive or synergistic way to form dicentrics. For the dose rates study, human blood was exposed to photons or electrons at dose rates ranging from low (where the dose was spread over 32 h) to extremely high (where the dose was delivered in a fraction of a microsecond). Potential effects of cytokine treatment on biodosimetry dose predictions were analyzed in irradiated blood subjected to Neupogen or Neulasta for 24 or 48 h at the concentration recommended to forestall manifestation of an acute radiation syndrome in bomb survivors. All measurements were performed using a robotic station, the Rapid Automated Biodosimetry Tool II, programmed to culture lymphocytes and score dicentrics in multiwell plates (the RABiT-II DCA). In agreement with classical concepts of radiation biology, the RABiT-II DCA calibration curves suggested that the frequency of dicentrics depends on the type of radiation and is modulated by changes in the dose rate. The resulting dose-response curves suggested an intermediate dicentric yields and additive effects of photons and IND-neutrons in the mixed field. At ultra-high dose rate (600 Gy/s), affected lymphocytes exhibited significantly fewer dicentrics (P < 0.004, t test). In contrast, we did not find the dose-response modification effects of radiomitigators on the yields of dicentrics (Bonferroni corrected P > 0.006, ANOVA test). This result suggests no bias in the dose predictions should be expected after emergency cytokine treatment initiated up to 48 h prior to blood collection for dicentric analysis.

Implementation of EPID transit dosimetry based on a through-air dosimetry algorithm.

PURPOSE: A method to perform transit dosimetry with an electronic portal imaging device (EPID) by extending the commercial implementation of a published through-air portal dose image (PDI) prediction algorithm Van Esch et al. [Radiother. Oncol. 71, 223-234 (2004)] is proposed and validated. A detailed characterization of the attenuation, scattering, and EPID response behind objects in the beam path is used to convert through-air PDIs into transit PDIs. METHODS: The EPID detector response beyond a range of water equivalent thicknesses (0-35 cm) and field sizes (3×3 to 22.2×29.6 cm(2)) was analyzed. A constant air gap between the phantom exit surface and the EPID was utilized. A model was constructed that accounts for the beam's attenuation along the central axis, the presence of phantom scattered radiation, the detector's energy dependent response, and the difference in EPID off-axis pixel response relative to the central pixel. The efficacy of the algorithm was verified by comparing predicted and measured PDIs for IMRT fields delivered through phantoms of increasing complexity. RESULTS: The expression that converts a through-air PDI to a transit PDI is dependent on the object's thickness, the irradiated field size, and the EPID pixel position. Monte Carlo derived narrow-beam linear attenuation coefficients are used to model the decrease in primary fluence incident upon the EPID due to the object's presence in the beam. This term is multiplied by a factor that accounts for the broad beam scatter geometry of the linac-phantom-EPID system and the detector's response to the incident beam quality. A 2D Gaussian function that models the nonuniformity of pixel response across the EPID detector plane is developed. For algorithmic verification, 49 IMRT fields were repeatedly delivered to homogeneous slab phantoms in 5 cm increments. Over the entire set of measurements, the average area passing a 3%∕3mm gamma criteria slowly decreased from 98% for no material in the beam to 96.7% for 35 cm of material in the beam. The same 49 fields were delivered to a heterogeneous slab phantom and on average, 97.1% of the pixels passed the gamma criteria. Finally, a total of 33 IMRT fields were delivered to the anthropomorphic phantom and on average, 98.1% of the pixels passed. The likelihood of good matches was independent of anatomical site. CONCLUSIONS: A prediction of the transit PDI behind a phantom or patient can be created for the purposes of treatment verification via an extension of the Van Esch through-air PDI algorithm. The results of the verification measurements through phantoms indicate that further investigation through patients during their treatments is warranted.

Sensitivity calibration procedures in optical-CT scanning of BANG 3 polymer gel dosimeters.

The dose response of the BANG 3 polymer gel dosimeter (MGS Research Inc., Madison, CT) was studied using the OCTOPUS laser CT scanner (MGS Research Inc., Madison, CT). Six 17 cm diameter and 12 cm high Barex cylinders, and 18 small glass vials were used to house the gel. The gel phantoms were irradiated with 6 and 10 MV photons, as well as 12 and 16 MeV electrons using a Varian Clinac 2100EX. Three calibration methods were used to obtain the dose response curves: (a) Optical density measurements on the 18 glass vials irradiated with graded doses from 0 to 4 Gy using 6 or 10 MV large field irradiations; (b) optical-CT scanning of Barex cylinders irradiated with graded doses (0.5, 1, 1.5, and 2 Gy) from four adjacent 4 x 4 cm2 photon fields or 6 x 6 cm2 electron fields; and (c) percent depth dose (PDD) comparison of optical-CT scans with ion chamber measurements for 6 x 6 cm2, 12 and 16 MeV electron fields. The dose response of the BANG3 gel was found to be linear and energy independent within the uncertainties of the experimental methods (about 3%). The slopes of the linearly fitted dose response curves (dose sensitivities) from the four field irradiations (0.0752 +/- 3%, 0.0756 +/- 3%, 0.0767 +/- 3%, and 0.0759 +/- 3% cm(-1) Gy(-1)) and the PDD matching methods (0.0768 +/- 3% and 0.0761 +/- 3% cm(-1) Gy(-1)) agree within 2.2%, indicating a good reproducibility of the gel dose response within phantoms of the same geometry. The dose sensitivities from the glass vial approach are different from those of the cylindrical Barex phantoms by more than 30%, owing probably to the difference in temperature inside the two types of phantoms during gel formation and irradiation, and possible oxygen contamination of the glass vial walls. The dose response curve obtained from the PDD matching approach with 16 MeV electron field was used to calibrate the gel phantom irradiated with the 12 MeV, 6 x 6 cm2 electron field. Three-dimensional dose distributions from the gel measurement and the Eclipse planning system (Varian Corporation, Palo Alto, CA) were compared and evaluated using 3% dose difference and 2 mm distance-to-agreement criteria.

A field size specific backscatter correction algorithm for accurate EPID dosimetry.

PURPOSE: Portal dose images acquired with an amorphous silicon electronic portal imaging device (EPID) suffer from artifacts related to backscattered radiation. The backscatter signal varies as a function of field size (FS) and location on the EPID. Most current portal dosimetry algorithms fail to account for the FS dependence. The ramifications of this omission are investigated and solutions for correcting the measured dose images for FS specific backscatter are proposed. METHODS: A series of open field dose images were obtained for field sizes ranging from 2 x 2 to 30 x 40 cm2. Each image was analyzed to determine the amount of backscatter present. Two methods to account for the relationship between FS and backscatter are offered. These include the use of discrete FS specific correction matrices and the use of a single generalized equation. The efficacy of each approach was tested on the clinical dosimetric images for ten patients, 49 treatment fields. The fields were evaluated to determine whether there was an improvement in the dosimetric result over the commercial vendor's current algorithm. RESULTS: It was found that backscatter manifests itself as an asymmetry in the measured signal primarily in the inplane direction. The maximum error is approximately 3.6% for 10 x 10 and 12.5 x 12.5 cm2 field sizes. The asymmetry decreased with increasing FS to approximately 0.6% for fields larger than 30 x 30 cm2. The dosimetric comparison between the measured and predicted dose images was significantly improved (p << .001) when a FS specific backscatter correction was applied. The average percentage of points passing a 2%, 2 mm gamma criteria increased from 90.6% to between 96.7% and 97.2% after the proposed methods were employed. CONCLUSIONS: The error observed in a measured portal dose image depends on how much its FS differs from the 30 x 40 cm2 calibration conditions. The proposed methods for correcting for FS specific backscatter effectively improved the ability of the EPID to perform dosimetric measurements. Correcting for FS specific backscatter is important for accurate EPID dosimetry and can be carried out using the methods presented within this investigation.